Advanced non-small-cell lung cancer patients with PD-L1 tumour expression of at least 50% have better survival outcomes with cemiplimab than platinum-doublet chemotherapy

Adding abemaciclib to endocrine therapy may help to combat invasive disease recurrence among high-risk early breast cancer patients with HR-positive, HER2-negative disease

No disease-free survival benefit with use of postoperative radiotherapy for N2 completely resected non-small-cell lung cancer

Heavily pretreated, metastatic urothelial cancer patients may benefit from sacituzumab govitecan

Online surveys have revealed the impact of the COVID-19 pandemic on the wellbeing of oncology professionals

Age could guide use of PSA testing and MRI prostate cancer screening in men with a germline BRCA1/2 mutation

Metastatic hormone receptor-positive, HER2-negative breast cancer patients may respond to sacituzumab govitecan

Circulating tumour DNA testing can help identify breast cancer mutations with targetable therapies